|
Status |
Public on Feb 28, 2017 |
Title |
EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas |
Organisms |
Homo sapiens; Mus musculus |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
28263309 |
|
Submission date |
Aug 09, 2016 |
Last update date |
May 15, 2019 |
Contact name |
Faizaan Mohammad |
E-mail(s) |
faizaan.mohammad@bric.ku.dk
|
Organization name |
BRIC
|
Street address |
Ole Maaloøs vej 5 Fourth Floor
|
City |
Copenhagen |
State/province |
Choose A State |
ZIP/Postal code |
2200 |
Country |
Denmark |
|
|
Platforms (2) |
GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
Samples (38)
|
|
This SuperSeries is composed of the following SubSeries:
|
GSE85385 |
EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas [RNA-Seq - mouse cell lines] |
GSE85386 |
EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas [ChIP-Seq mouse cell lines] |
GSE85387 |
EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas [ChIP-Seq human cell lines] |
GSE85388 |
EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas [RNA-Seq mouse tumors] |
|
Relations |
BioProject |
PRJNA338311 |